S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

S&E-Korea

More Like This

PR Newswire associated0

Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports

PR Newswire associated0

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Exidavnemab phase 2a study expanded to include MSA patients

Business Wire logo

ReLive Biotechnologies Announces NDA Approval of SpheChon 10-70 spheroids/cm² by the HSA in Singapore, Marking a Milestone in ReLive’s Global Endeavors

Business Wire logo

Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

PR Newswire associated0

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration